Egypt

The Egyptian Drug Authority (EDA), established under Law No. 151 of 2019, serves as the primary national regulatory body overseeing the registration, licensing, and post-market surveillance of pharmaceuticals, medical devices, diagnostics, and increasingly digital health solutions in Egypt. The EDA replaced the former Central Administration of Pharmaceutical Affairs (CAPA) and operates under the broader framework of the Ministry of Health and Population (MoHP). The general approval process requires applicants to submit a registration dossier, undergo technical review by EDA committees, and in many cases fulfill local facility inspection requirements before a marketing authorization is granted. Medical devices are classified into four risk-based categories (Class A through D), with higher-risk devices subject to more rigorous conformity assessment and clinical evaluation requirements.

The EDA formally accepts dossiers structured according to the Common Technical Document (CTD) format, aligning Egypt's submission standards with international norms and facilitating convergence with regional regulatory frameworks. A locally registered legal representative or agent is mandatory for all foreign manufacturers seeking product registration, and a certificate of pharmaceutical product (CPP) from the country of origin is typically required. Egypt has pursued a number of regulatory modernization reforms in recent years, including the introduction of abbreviated registration pathways for products already approved by stringent regulatory authorities (SRAs) such as the US FDA, EMA, or Health Canada, which can significantly compress review timelines. The EDA has also expanded its digital submission portal to improve transparency and procedural efficiency, and is actively working toward alignment with the African Medicines Regulatory Harmonization (AMRH) initiative.

Public procurement of health products in Egypt is centrally coordinated through the Ministry of Health and Population (MoHP), with significant roles played by the Egyptian Drug Authority for product eligibility and the General Authority for Government Services (GAGS) overseeing broader public tendering. The Central Purchasing Unit within the MoHP manages national tender processes for pharmaceuticals, medical devices, and diagnostics destined for public hospitals, primary health care facilities, and national disease control programs. Tenders are typically published through official government channels and the Egyptian government's tender portal, and awards are governed by Law No. 182 of 2018 on public procurement. Price negotiation and registration status with the EDA are prerequisites for participation in public tenders. The National Health Insurance Authority (NHIA), which is progressively rolling out Universal Health Insurance (UHI) coverage under Law No. 2 of 2018, is an increasingly important procurement stakeholder, with its formulary and pricing decisions shaping long-term market access for health products across covered governorates.

The private sector represents a substantial and growing channel in Egypt, encompassing private hospital chains, retail pharmacy networks, and private diagnostic laboratories, all of which procure independently through distributors and local agents. Egypt also benefits from donor-funded procurement channels: UNICEF, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and USAID-affiliated programs such as PEPFAR contribute to the supply of essential medicines, diagnostics, and commodities for specific disease areas including HIV, tuberculosis, and malaria. Gavi-supported vaccine procurement channels are also relevant for immunization program products. Egypt has a longstanding policy emphasis on supporting domestic pharmaceutical manufacturing, and local manufacturers may benefit from preferential pricing margins and priority consideration in public tenders. Foreign manufacturers are increasingly incentivized to pursue local manufacturing partnerships, technology transfer agreements, or toll-manufacturing arrangements with Egyptian facilities as a strategy to strengthen market positioning and align with national industrial policy objectives.